How should dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor such as clopidogrel, prasugrel, or ticagrelor) be managed before and after elective surgery?

Management of Dual Antiplatelet Therapy Before and After Elective Surgery

For patients on DAPT undergoing elective non-cardiac surgery, stop the P2Y12 inhibitor (clopidogrel 5 days, prasugrel 7 days, ticagrelor 3-5 days before surgery) while continuing aspirin perioperatively, then resume the P2Y12 inhibitor within 24 hours postoperatively 1.

Preoperative Management

Timing of Surgery After Stent Placement

• Postpone elective surgery until completion of the full DAPT course when it does not pose major life-threatening or functional risk 2
• If postponement is impossible, delay surgery beyond 1 month after any stent implantation, regardless of stent type 2
• For patients with recent myocardial infarction or high-risk stents, postpone for up to 6 months 2
• Surgery within the first month should only occur in hospitals with 24/7 catheterization laboratory availability 2

P2Y12 Inhibitor Discontinuation Timeline

The specific agent determines the preoperative discontinuation period:

• Clopidogrel: Stop 5 days before surgery 1, 2
• Prasugrel: Stop 7 days before surgery 1, 3
• Ticagrelor: Stop 3-5 days before surgery 1

These timelines allow adequate platelet function recovery while minimizing thrombotic risk. The FDA label for prasugrel explicitly states to discontinue at least 7 days prior to any surgery when possible 3.

Aspirin Management

Continue aspirin throughout the perioperative period 1, 2. This recommendation applies to most surgical procedures, with rare exceptions for:

• Intracranial surgery
• Spinal surgery within the medullary canal
• Posterior chamber eye surgery
• Procedures where bleeding occurs in closed spaces 2

If aspirin must be stopped, discontinue ≤7 days (not 7-10 days) before surgery and resume as early as possible, ideally the same day postoperatively 1.

Special Consideration: Recent Stent Patients (6-12 Weeks)

For patients with coronary stents placed within the last 6-12 weeks requiring elective surgery, either continue both antiplatelet agents or stop one agent within 7-10 days of surgery 1. This decision depends on:

• Bleeding risk of the specific procedure
• Risk of acute coronary syndrome/stent thrombosis
• Individual patient thrombotic risk factors

This represents a critical decision point requiring multidisciplinary discussion with cardiology.

Postoperative Management

Resumption of Antiplatelet Therapy

Resume the P2Y12 inhibitor within 24 hours after surgery (not >24 hours) 1. This early resumption is crucial given the increased thrombotic risk in patients requiring DAPT. If possible, resume within 24-72 hours 2.

Resume with the same P2Y12 inhibitor used preoperatively 2. The evidence does not support clear recommendations regarding loading doses upon resumption.

Aspirin Resumption

If aspirin was discontinued, resume within 24 hours postoperatively 1.

CABG Surgery: Different Rules Apply

For patients undergoing coronary artery bypass grafting:

• Continue aspirin perioperatively 1, 2
• Stop P2Y12 inhibitors preoperatively using the same timelines (clopidogrel 5 days, prasugrel 7 days, ticagrelor 3-5 days) 1
• Resume both agents within 24 hours after CABG 1
• Delay resumption if post-CABG thrombocytopenia develops (platelet count <50,000/μL) 1

The rationale: Continuing P2Y12 inhibitors during CABG increases bleeding, transfusions, and surgical re-explorations without clear antithrombotic benefit 2.

Regional Anesthesia Considerations

Neuraxial Blocks

• Aspirin monotherapy is not a contraindication to spinal anesthesia if benefit-risk ratio is favorable 2
• P2Y12 inhibitors are contraindicated for central neuraxial anesthesia 2
• Single-puncture spinal anesthesia is preferable to epidural when aspirin is continued 2

Peripheral Nerve Blocks

• Low-risk superficial blocks (femoral, axillary, popliteal sciatic): Can be performed on DAPT if benefit-risk ratio favors it 2
• High-risk deep blocks (infraclavicular, para-sacral sciatic, posterior lumbar plexus): Acceptable on aspirin monotherapy only; contraindicated with P2Y12 inhibitors unless discontinued per standard timelines 2
• Use ultrasound guidance by experienced operators 2

Critical Pitfalls to Avoid

1. Do not use platelet function testing routinely to guide perioperative management 1. While it may have limited utility in specific scenarios (e.g., patients recently started on P2Y12 inhibitors before CABG), routine use is not recommended.

2. Do not use heparin or LMWH as "bridging therapy" to replace antiplatelet agents 2. These do not protect against coronary or stent thrombosis and increase bleeding risk.

3. Avoid NSAIDs perioperatively in patients on DAPT 2. Coxibs may be used if necessary.

4. Do not stop prasugrel in patients likely to undergo urgent CABG 3. The FDA label specifically warns against starting prasugrel in such patients.

5. Premature discontinuation of DAPT increases risk of stent thrombosis, MI, and death 3. If bleeding occurs postoperatively, manage without discontinuing antiplatelet therapy when possible 3.

Exceptional High-Risk Scenarios

For the rare situation where surgery cannot be delayed beyond 1 month post-stent and both agents must be stopped (e.g., neurosurgery), bridging with intravenous antiplatelet agents (tirofiban or cangrelor) can be considered on a case-by-case basis, though this is off-label use 2. This requires:

• Intensive care unit setting
• Hospital with 24/7 catheterization laboratory
• Multidisciplinary consensus

The evidence for this approach is limited, representing expert opinion rather than trial data 2.